Mutant receptor tyrosine kinases (RTK (mutant), no single canonical abbreviation for all mutant forms)

Receptor tyrosine kinases (RTKs) are a large family of transmembrane cell-surface receptors that transmit signals from extracellular growth factors, cytokines, and hormones to intracellular signaling networks. Mutant receptor tyrosine kinases result from genetic alterations (including point mutations, deletions, insertions, amplifications, and gene fusions) that often cause ligand-independent or constitutive receptor activation, driving oncogenic signaling and uncontrolled cell proliferation. Such mutations are especially relevant in cancer pathogenesis and serve as important therapeutic targets for various small-molecule inhibitors and monoclonal antibodies. There are about 58 different RTKs in humans, categorized into 20 subfamilies. Commonly mutated RTKs in human cancers include EGFR, HER2, ALK, FGFR1, PDGFR, RET, and others. The clinical response to RTK inhibitors depends critically on mutation status, which also serves as both a biomarker for drug selection and a determinant of acquired resistance. While therapies targeting mutant RTKs have improved outcomes in several malignancies, issues with resistance and toxicity remain significant challenges[1][2][3][5][6][7]. Note: For structured data, it is essential to specify the particular mutant RTK by gene and alteration (e.g., "Epidermal growth factor receptor L858R mutant") for accurate mapping and drug association. The current term is too generic for precise annotation.

Other names

Mutant RTKOncogenic receptor tyrosine kinaseActivated RTK (mutant)

- Inhibition of kinase activity (by blocking ATP binding or substrate binding pockets) - Prevention of downstream signaling (e.g., MAPK, PI3K/AKT pathways) - Induction of apoptosis in cells dependent on mutant RTK signaling[3][6][9]